STEMLINE THERAPEUTICS INC

NEW YORK, NY · CIK 0001264587 · Biotech · Acquired

Tagraxofusp-erzs, a CD123-directed cytotoxin for treating blastic plasmacytoid dendritic cell neoplasm

stemline.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$2.6M
3 Form D · Jan 2012
177 months since last filing
Contracts
—
No federal contracts on record
Patents
40
11 granted · 29 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,250,000
Private capital raisedForm D · SEC$600,000
Private capital raisedForm D · SEC$740,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2529ImmuneBridge Inc.—$16M
2530IpiNovyx Bio, Inc.—$7.0M
2531Lang Artificial Intelligence, Inc.—$11M
2532STEMLINE THERAPEUTICS INC—$2.6M
2533Form Bio—$16M
2534A2 THERAPEUTICS, INC.——
2535Deverra Therapeutics—$2.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Ronald BentsurDirector
  • Ivan BergsteinDirector · Executive Officer
  • Ivan Bergstein, M.D.Director · Executive Officer

Patents

USPTO · 11 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.